© 2021 MJH Life Sciences™ and Neurology Live. All rights reserved.
AHS
Matthew Robbins, MD: Headaches Associated With COVID-19
July 21, 2020
The director of the Neurology Residency Program at Weill Cornell Medicine highlighted some of the differences in types of headaches that patients with COVID-19 experience, as well as overall takeaways from the pandemic itself.
Fred Cohen, MD: OnabotulinumtoxinA and CGRP Combination Treatment
July 15, 2020
The internal medicine resident physician at Montefiore Health System provided an overview of the study he and colleagues conducted on patients using onabotulinumtoxinA and CGRP agents in tandem.
Kathleen Digre, MD, on Eye Pain and Photophobia in Migraine
July 14, 2020
Despite its ranking as a "most bothersome symptom" among migraineurs, eye pain and photophobia often go ignored or under-treated in the headache clinic.
Roger Cady, MD: Rapid Effect of Eptinezumab on Migraine
July 14, 2020
The head of Neurology Medical at Lundbeck Seattle Biopharmaceuticals offers perspective on the findings and what impact eptinezumab may have on migraine care.
Total Migraine Pain Burden Reduced With Galcanezumab in Post-Hoc Analysis
July 13, 2020
Treatment with galcanezumab (Emgality; Eli Lilly) was associated with improvements in total pain burden for patients with both chronic and episodic migraine compared to placebo groups.
Matthew Robbins, MD: Residency During COVID-19
July 09, 2020
The director of the Neurology Residency Program at Weill Cornell Medicine provided insight on the experience residents have had during the COVID-19 pandemic and how it has shaped them for the future.
Chia-Chun Chiang, MD: Collecting Real-World Data Following FDA Approvals
July 07, 2020
The neurologist at Mayo Clinic in Phoenix, Arizona, detailed the importance of further studies of FDA approved medications in different patient populations.
Long-Term Safety Study Confirms Efficacy of ADAM Zolmitriptan in Acute Migraine
July 07, 2020
The FDA accepted an NDA for Zosano’s ADAM zolmitriptan (Qytripta) in the acute treatment of migraine in early March, with a PDUFA date set for mid-October 2020.
Chia-Chun Chiang, MD: Variations in FDA Approved Migraine Medications
June 27, 2020
The neurologist at Mayo Clinic in Phoenix, Arizona, discussed the growing variety of treatment options and the progress the migraine community has made on the management of this disease.
Migraine Care During a Pandemic: Takeaways for the Future
June 24, 2020
In part 2 of this interview, Matthew Robbins, MD, director of the Neurology Residency Program at Weill Cornell Medicine, describes the lessons he and his residents have learned during the COVID-19 pandemic and how they'll impact the future of care.